4.5 Review

Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature

期刊

AMERICAN JOURNAL OF INFECTION CONTROL
卷 49, 期 2, 页码 238-246

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.ajic.2020.06.213

关键词

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Coronavirus; Pandemic; Comorbidity; Epidemiology; Fatality or mortality

向作者/读者索取更多资源

Hypertension, diabetes, and cardiovascular diseases are the most common comorbidities among COVID-19 positive patients across major epicenters worldwide. While having comorbidities is associated with increased disease severity, there is no clear association found between these risk factors and increased risk of fatality.
Introduction: On February 11, 2020 WHO designated the name COVID-19 for the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel virus that quickly turned into a global pandemic. Risks associated with acquiring the virus have been found to most significantly vary by age and presence of underlying comorbidity. In this rapid literature review we explore the prevalence of comorbidities and associated adverse outcomes among individuals with COVID-19 and summarize our findings based on information available as of May 15, 2020. Methods: A comprehensive systematic search was performed on PubMed, Medline, Scopus, Embase, and Google Scholar to find articles published until May 15, 2020. All relevant articles providing information on PCR tested COVID-19 positive patient population with clinical characteristics and epidemiological information were selected for review and analysis. Results: A total of 27 articles consisting of 22,753 patient cases from major epicenters worldwide were included in the study. Major comorbidities seen in overall population were CVD (8.9%), HTN (27.4%), Diabetes (17.4%), COPD (7.5%), Cancer (3.5%), CKD (2.6%), and other (15.5%). Major comorbidity specific to countries included in the study were China (HTN 39.5%), South Korea (CVD 25.6%), Italy (HTN 35.9%), USA (HTN 38.9%), Mexico, (Other 42.3%), UK (HTN 27.8%), Iran (Diabetes 35.0%). Within fatal cases, an estimated 84.1% had presence of one or more comorbidity. Subgroup analysis of fatality association with having comorbidity had an estimated OR 0.83, CI [0.60-0.99], p<0.05. Conclusions: Based on our findings, hypertension followed by diabetes and cardiovascular diseases were the most common comorbidity seen in COVID-19 positive patients across major epicenters world-wide. Although having one or more comorbidity is linked to increased disease severity, no clear association was found between having these risk factors and increased risk of fatality. (C) 2020 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据